Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariane Laparra

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|February 27, 2019
The Frequencies of Immunosuppressive Cells in Adipose Tissue Differ in Human, Non-human Primate, and Mouse ModelsAriane Laparra, Sabine Tricot, Mélanie Le Van, et al.
JAMA Oncology|June 7, 2019
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With CancerAudrey Simonaggio, Jean Marie Michot, Anne Laure Voisin, et al.
Journal of Clinical Medicine|May 13, 2023
Psychiatric Symptoms and Cognitive Disorders in Behçet's Disease: A Single-Center, Cross-Sectional StudyFanny Urbain, Isabelle Hardy-Léger, Ghaidaa Adebs-Nasser, et al.
Aging|September 13, 2021
Circulating acetylated polyamines correlate with Covid-19 severity in cancer patientsMélanie Bourgin, Lisa Derosa, Carolina Alves Costa Silva, et al.
JHEP Reports : Innovation in Hepatology|February 9, 2026
Plasma exchange as potential treatment of severe immune checkpoint inhibitor-induced hepatitisLucy Meunier, Clement Monet, Antonio Saviano, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2023
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncologyEmily Alouani, Ariane Laparra, Audrey Perret, et al.
Cancer Treatment Reviews|May 10, 2024
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendationsLayal Rached, Ariane Laparra, Madona Sakkal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2021
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment studyMarion Panhaleux, Olivier Espitia, Benjamin Terrier, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive reviewArthur Géraud, Thomas Hueso, Ariane Laparra, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|February 27, 2019
The Frequencies of Immunosuppressive Cells in Adipose Tissue Differ in Human, Non-human Primate, and Mouse ModelsAriane Laparra, Sabine Tricot, Mélanie Le Van, et al.
JAMA Oncology|June 7, 2019
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With CancerAudrey Simonaggio, Jean Marie Michot, Anne Laure Voisin, et al.
Journal of Clinical Medicine|May 13, 2023
Psychiatric Symptoms and Cognitive Disorders in Behçet's Disease: A Single-Center, Cross-Sectional StudyFanny Urbain, Isabelle Hardy-Léger, Ghaidaa Adebs-Nasser, et al.
Aging|September 13, 2021
Circulating acetylated polyamines correlate with Covid-19 severity in cancer patientsMélanie Bourgin, Lisa Derosa, Carolina Alves Costa Silva, et al.
JHEP Reports : Innovation in Hepatology|February 9, 2026
Plasma exchange as potential treatment of severe immune checkpoint inhibitor-induced hepatitisLucy Meunier, Clement Monet, Antonio Saviano, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2023
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncologyEmily Alouani, Ariane Laparra, Audrey Perret, et al.
Cancer Treatment Reviews|May 10, 2024
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendationsLayal Rached, Ariane Laparra, Madona Sakkal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2021
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment studyMarion Panhaleux, Olivier Espitia, Benjamin Terrier, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive reviewArthur Géraud, Thomas Hueso, Ariane Laparra, et al.
Pageof 3